EClinicalMedicine (Jun 2024)

Nutritional supplementation in children with severe pneumonia in Uganda and Kenya (COAST-Nutrition): a phase 2 randomised controlled trialResearch in context

  • Sarah Kiguli,
  • Peter Olupot-Olupot,
  • Mainga Hamaluba,
  • Elisa Giallongo,
  • Karen Thomas,
  • Florence Alaroker,
  • Robert O. Opoka,
  • Abner Tagoola,
  • Shela Oyella,
  • Damalie Nalwanga,
  • Eva Nabawanuka,
  • William Okiror,
  • Margaret Nakuya,
  • Denis Amorut,
  • Rita Muhindo,
  • Ayub Mpoya,
  • Hellen Mnjalla,
  • Emmanuel Oguda,
  • Thomas N. Williams,
  • David A. Harrison,
  • Kathy Rowan,
  • Andre Briend,
  • Kathryn Maitland

Journal volume & issue
Vol. 72
p. 102640

Abstract

Read online

Summary: Background: Severe pneumonia in African children results in poor long-term outcomes (deaths/readmissions) with undernutrition as a key risk factor. We hypothesised additional energy/protein-rich Ready-to-Use Therapeutic Foods (RUTF) would meet additional nutritional requirements and improve outcomes. Methods: COAST-Nutrition was an open-label Phase 2 randomised controlled trial in children (aged 6 months-12 years) hospitalised with severe pneumonia (and hypoxaemia, SpO2 99%). By Day 90, there was no significant difference in the composite endpoint (probabilistic index 0.49, 95% CI 0.45–0.53, p = 0.74). Respective 90-day mortality (13/420 3.1% vs 14/421 3.3%) and MUAC increment (0.54 (SD 0.85) vs 0.55 (SD 0.81)) were similar between arms. There was no difference in any anthropometric secondary endpoints to Day 28, 90 or 180 except skinfold thickness at Day 28 and Day 90 was greater in the RUTF arm. Serious adverse events were higher in the RUTF arm (n = 164 vs 108), mainly due to hospital readmission for acute illness (54/387 (14%) vs 37/375 (10%). Interpretation: Our study suggested that nutritional supplementation with RUTF did not improve outcomes to 180 days in children with severe pneumonia. Funding: This trial is part of the EDCTP2 programme (grant number RIA-2016S-1636-COAST-Nutrition) supported by the European Union, and UK Joint Global Health Trials scheme: Medical Research Council, Department for International Development, Wellcome Trust (grant number MR/L004364/1, UK).

Keywords